Advanced glycation end products and its soluble receptor in AOSD pathogenic role
碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 101 === Adult onset Still’s disease (AOSD) is a chronic inflammatory disease characterized by fever of unknown origin, arthritis, and skin rash. However the etiopathogenesis of AOSD remains unclear. Studies have shown that the levels of advanced glycation end produc...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2013
|
Online Access: | http://ndltd.ncl.edu.tw/handle/64966087533341905520 |
id |
ndltd-TW-101NCHU5105002 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-101NCHU51050022017-10-29T04:34:16Z http://ndltd.ncl.edu.tw/handle/64966087533341905520 Advanced glycation end products and its soluble receptor in AOSD pathogenic role 糖化終產物及其可溶性接受器在成人型史迪兒氏症致病機轉之角色 Yen- Ching Wu 吳燕晴 碩士 國立中興大學 生命科學院碩士在職專班 101 Adult onset Still’s disease (AOSD) is a chronic inflammatory disease characterized by fever of unknown origin, arthritis, and skin rash. However the etiopathogenesis of AOSD remains unclear. Studies have shown that the levels of advanced glycation end products (AGEs) were associated with chronic inflammation, and were positively correlated with disease duration of systemic lupus erythematosus (SLE). Although AOSD is also an inflammatory disease, there is no any data regarding AGEs in this disease. In order to explore the relationship between AOSD and AGEs as well as their receptors, we enrolled 52 patients with AOSD, 36 patients with SLE, and 16 healthy volunteers, and used the enzyme-linked immunosorbent assay (ELISA) to detect plasma (or serum) levels of AGEs and their soluble receptors for advanced glycation end products (sRAGE). Our results showed plasma (or serum) AGEs levels were significantly higher in patients with active AOSD compared with healthy controls (mean± SEM; 19.47± 1.84 µg/ ml vs. 8.45± 0.97μg/ ml; p < 0.001). Plasma (or serum) AGEs levels were also significantly higher in patients with active AOSD compared with inactive AOSD (mean± SEM; 7.52± 0.57μg/ ml; p < 0.001). Whereas, plasma (or serum) sRAGE levels were significantly lower in patients with active AOSD compared with healthy controls (mean± SEM; 650.7± 59.0 pg/ml vs.1129.7± 98.7 pg/ ml; p< 0.001). Plasma (or serum) sRAGE levels were lower in patients with active AOSD compared with inactive AOSD (mean± SEM; 985.3± 106.9 pg/ ml; p < 0.05). Similarly, plasma (or serum) AGEs levels were higher and sRAGE levels were lower in patients with active SLE compared with inactive SLE or healthy control. Plasma (or serum) AGEs levels were also positively correlated with activity markers of AOSD including a activity score (r =0.836 ; p < 0.001)、ferritin ( r =0.372;p <0.05)、ESR(r =0.413;p <0.005)、CRP( r =0.396;p <0.005).In conclusion our results suggested that AGEs and sRAGE could be useful markers for clinical physician to monitor disease activity of AOSD. Der- Yuan Chen 陳得源 2013 學位論文 ; thesis 47 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 101 === Adult onset Still’s disease (AOSD) is a chronic inflammatory disease characterized by fever of unknown origin, arthritis, and skin rash. However the etiopathogenesis of AOSD remains unclear. Studies have shown that the levels of advanced glycation end products (AGEs) were associated with chronic inflammation, and were positively correlated with disease duration of systemic lupus erythematosus (SLE). Although AOSD is also an inflammatory disease, there is no any data regarding AGEs in this disease. In order to explore the relationship between AOSD and AGEs as well as their receptors, we enrolled 52 patients with AOSD, 36 patients with SLE, and 16 healthy volunteers, and used the enzyme-linked immunosorbent assay (ELISA) to detect plasma (or serum) levels of AGEs and their soluble receptors for advanced glycation end products (sRAGE). Our results showed plasma (or serum) AGEs levels were significantly higher in patients with active AOSD compared with healthy controls (mean± SEM; 19.47± 1.84 µg/ ml vs. 8.45± 0.97μg/ ml; p < 0.001). Plasma (or serum) AGEs levels were also significantly higher in patients with active AOSD compared with inactive AOSD (mean± SEM; 7.52± 0.57μg/ ml; p < 0.001). Whereas, plasma (or serum) sRAGE levels were significantly lower in patients with active AOSD compared with healthy controls (mean± SEM; 650.7± 59.0 pg/ml vs.1129.7± 98.7 pg/ ml; p< 0.001). Plasma (or serum) sRAGE levels were lower in patients with active AOSD compared with inactive AOSD (mean± SEM; 985.3± 106.9 pg/ ml; p < 0.05). Similarly, plasma (or serum) AGEs levels were higher and sRAGE levels were lower in patients with active SLE compared with inactive SLE or healthy control. Plasma (or serum) AGEs levels were also positively correlated with activity markers of AOSD including a activity score (r =0.836 ; p < 0.001)、ferritin ( r =0.372;p <0.05)、ESR(r =0.413;p <0.005)、CRP( r =0.396;p <0.005).In conclusion our results suggested that AGEs and sRAGE could be useful markers for clinical physician to monitor disease activity of AOSD.
|
author2 |
Der- Yuan Chen |
author_facet |
Der- Yuan Chen Yen- Ching Wu 吳燕晴 |
author |
Yen- Ching Wu 吳燕晴 |
spellingShingle |
Yen- Ching Wu 吳燕晴 Advanced glycation end products and its soluble receptor in AOSD pathogenic role |
author_sort |
Yen- Ching Wu |
title |
Advanced glycation end products and its soluble receptor in AOSD pathogenic role |
title_short |
Advanced glycation end products and its soluble receptor in AOSD pathogenic role |
title_full |
Advanced glycation end products and its soluble receptor in AOSD pathogenic role |
title_fullStr |
Advanced glycation end products and its soluble receptor in AOSD pathogenic role |
title_full_unstemmed |
Advanced glycation end products and its soluble receptor in AOSD pathogenic role |
title_sort |
advanced glycation end products and its soluble receptor in aosd pathogenic role |
publishDate |
2013 |
url |
http://ndltd.ncl.edu.tw/handle/64966087533341905520 |
work_keys_str_mv |
AT yenchingwu advancedglycationendproductsanditssolublereceptorinaosdpathogenicrole AT wúyànqíng advancedglycationendproductsanditssolublereceptorinaosdpathogenicrole AT yenchingwu tánghuàzhōngchǎnwùjíqíkěróngxìngjiēshòuqìzàichéngrénxíngshǐdíérshìzhèngzhìbìngjīzhuǎnzhījiǎosè AT wúyànqíng tánghuàzhōngchǎnwùjíqíkěróngxìngjiēshòuqìzàichéngrénxíngshǐdíérshìzhèngzhìbìngjīzhuǎnzhījiǎosè |
_version_ |
1718557292835635200 |